Rapid Acting Insulin Market Size Worth $11.4 billion by 2027

Published Date: 12-May-2021

Special Offering :

Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support

According to a new report Global Rapid Acting Insulin Market, published by KBV research, The Global Rapid Acting Insulin Market size is expected to reach $11.4 billion by 2027, rising at a market growth of 5.6% CAGR during the forecast period.

The Insulin Lispro market dominated the Global Rapid Acting Insulin Market by Product Type in 2020, and would continue to be a dominant market till 2027. The Insulin Aspart market is expected to witness a CAGR of 5.9% during (2021 - 2027).

The Drug Stores & Retail Pharmacies market dominated the Global Rapid Acting Insulin Market by Distribution Channel in 2020, growing at a CAGR of 5.2 % during the forecast period. The Hospital Pharmacies market is experiencing a CAGR of 5.9% during (2021 - 2027). The Online Providers market is expected to witness a CAGR of 6.5% during (2021 - 2027).

The North America market dominated the Global Rapid Acting Insulin Market by Region in 2020. On the other hand, Asia-Pacific would exhibit a prominent growth rate in the global rapid-acting insulin market, due to the adoption of modern & western lifestyle behaviors and the growing occurrences of obesity. This would create many growth avenues for the global rapid-acting insulin market during the forecast period.

Full Report: https://www.kbvresearch.com/rapid-acting-insulin-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Merck & Co., Inc., Sanofi S.A., Novo Nordisk A/S, Eli Lilly and Company, Adocia SA, Biocon Limited, Gan & Lee Pharmaceuticals, Geropharm LLC, Wockhardt Ltd., and MannKind Corporation.

Global Rapid Acting Insulin Market Segmentation

By Product Type

  • Insulin Lispro
  • Insulin Aspart
  • Insulin Glulisine

By Indication

  • Type 2 Diabetes
  • Type 1 Diabetes

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Providers

By Geography

  • North America
    • US
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Germany
    • UK
    • France
    • Russia
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Singapore
    • Malaysia
    • Rest of Asia Pacific
    • Brazil
    • Argentina
    • UAE
    • Saudi Arabia
    • South Africa
    • Nigeria
    • Rest of LAMEA

Companies Profiled

  • Merck & Co., Inc.
  • Sanofi S.A.
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Adocia SA
  • Biocon Limited
  • Gan & Lee Pharmaceuticals
  • Geropharm LLC
  • Wockhardt Ltd.
  • MannKind Corporation

Unique Offerings from KBV Research

  • Exhaustive coverage
  • The highest number of market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free

Rapid Acting Insulin Market Related Reports:

North America Market

Europe Market

Asia Pacific Market

LAMEA Market

Request a Free Sample Copy

Why Choose Us

  • 24/7 Research support
    Get your queries resolved from an industry expert. Request for a free product review before report purchase.

  • Information security
    Your personal and confidential information is safe and secure.